US5648100A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Microspheres useful for therapeutic vascular occlusions and injectable solutions containing the same
Assignee: Biosphere Medical SA
•
Filing: 1995-06-06
•
Granted: 1997-07-15
•
Expires: 2015-06-06
Abstract
Abstract The present invention concerns the use of microspheres for therapeutic embolization consisting of a hydrophilic acrylic copolymer coated with a cell adhesion promoter.
Inventors
- 👤 Egisto Boschetti
- 👤 Michel Brouard
- 👤 Ludovic Drouet
- 👤 Pierre Girot
- 👤 Alexandre Laurent
- 👤 Michel Wassef
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 09:33
CPC Classifications
A; A61; A61L; A61L24/00; A61L24/04; A61L24/06; A61K; A61K9/00; A61K9/14; A61K9/16; A61K9/167; A61K9/1676; A61P; A61P9/00; A61L2400/00; A61L2400/06; A61L2430/00; A61L2430/36
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
95 words
An injectable solution suitable for the embolization of microspheres, which comprises a microsphere having a diameter ranging between about 10 to about 2000 μm wherein said microsphere comprises a copolymer comprising, in copolymerized form, about 25 to about 98% neutral hydrophilic acrylic monomer by weight, about 2 to about 50% difunctional monomer by weight, about 0 to about 50% by weight of one or more monomers having a cationic charge, and about 1 to about 30% by weight of a functionalized monomer making possible the detection of the microsphere, coated with a cell adhesion promoter.
Claim 2
Dependent Claim
95 words
An injectable solution suitable for the embolization of microspheres, which comprises a microsphere having a diameter ranging between about 10 to about 2000 μm wherein said microsphere comprises a copolymer comprising, in copolymerized form, about 25 to about 98% neutral hydrophilic acrylic monomer by weight, about 2 to about 50% difunctional monomer by weight, about 0 to about 50% by weight of one or more monomers having a cationic charge, and about 1 to about 30% by weight of a functionalized monomer making possible the detection of the microsphere, coated with a cell adhesion promoter.
Claim 3
Dependent Claim
34 words
An injectable solution according to claim 1, characterized in that the functionalized monomer comprises a monomer covalently linked to a marking agent selected from the group consisting of dyes, imaging agents and contrasting agents.
Claim 4
Dependent Claim
34 words
An injectable solution according to claim 2, characterized in that the functionalized monomer is selected from the group consisting of N-acryloyl hexamethylene-anthraquinone dyes, N-acryloyl hexamethylene-azoic dyes, (acrylamido-3-propionamido)-3-triiodo-2,4,5-benzoic acid or polymers thereof, and acrylamido-3-triiodo-2,4,6-benzoic polyacid.
Claim 5
Dependent Claim
24 words
An injectable solution according to claim 2, characterized in that the marking agent is directly introduced in powdered form in the initial monomer solution.
Claim 6
Dependent Claim
38 words
An injectable solution for therapeutic embolization, comprising a microsphere, having a diameter ranging between about 10 to about 2000 μm, wherein said microsphere comprises a hydrophilic acrylic copolymer coated with a cell adhesion promoter and a marking agent.
Claim 7
Dependent Claim
38 words
An injectable solution for therapeutic embolization, comprising a microsphere, having a diameter ranging between about 10 to about 2000 μm, wherein said microsphere comprises a hydrophilic acrylic copolymer coated with a cell adhesion promoter and a marking agent.
Claim 8
Independent Claim
26 words
A method for the therapeutic embolization of microspheres which comprises administering to a mammal an injectable solution according to claims 1, 2, 3, 4 or 5.
Claim 9
Dependent Claim
53 words
The method according to claim 6, characterized in that the acrylic copolymer comprises, in copolymerized form, about 25 to about 98% neutral hydrophilic acrylic monomer by weight, about 2 to about 50% difunctional monomer by weight, and about 0 to about 50% by weight of one or more monomers carrying a cationic charge.
Claim 10
Dependent Claim
25 words
The method according to claim 7, characterized in that the neutral hydrophilic acrylic monomer is selected from the group consisting of acrylamides, methacrylamides and hydroxymethlymethacrylate.
Claim 11
Dependent Claim
23 words
The method according to claim 7, characterized in that the difunctional monomer is selected from the group consisting of N,N'-methylene-bis-acrylamide, N'N'-diallyltartradiamide and glyoxal-bis-acrylamide.
Claim 12
Dependent Claim
25 words
The method according to claim 7, characterized in that the monomer having a cationic charge is a monomer having a tertiary and/or quaternary amine function.
Claim 13
Dependent Claim
54 words
An injectable solution according to claim 5, characterized in that the acrylic copolymer comprises, in copolymerized form, about 25 to about 98% neutral hydrophilic acrylic monomer by weight, about 2 to about 50% difunctional monomer by weight, and about 0 to about 50% by weight of one ore more monomers carrying a cationic charge.
Claim 14
Dependent Claim
26 words
An injectable solution according to claim 11, characterized in that the neutral hydrophilic acrylic monomer is selected from the group consisting of acrylamides, methacrylamides and hydroxymethlymethacrylate.
Claim 15
Dependent Claim
24 words
An injectable solution according to claim 11, characterized in that the difunctional monomer is selected from the group consisting of N,N'-methylene-bis-acrylamide, N'N'-diallyltartradiamide and glyoxal-bis-acrylamide.
Claim 16
Dependent Claim
26 words
An injectable solution according to claim 11, characterized in that the monomer having a cationic charge is a monomer having a tertiary and/or quaternary amine function.
Claim 17
Dependent Claim
39 words
An injectable solution according to claim 5, characterized in that the cell adhesion promoter is selected from the group consisting of collagen, gelatin, glucosaminoglycans, fibronectin, lectins, polycations and natural biological cell adhesion agents or synthetic biological cell adhesion agents.
Claim 18
Dependent Claim
26 words
An injectable solution according to claim 15, characterized in that the cell adhesion promoter represents about 1 to about 50% by volume of the acrylic copolymer.
Claim 19
Independent Claim
48 words
A method for the therapeutic embolization of microspheres in a mammal which comprises administering to a mammal a microsphere, having a diameter ranging between about 10 to about 2000 μm, wherein said microsphere comprises a hydrophilic acrylic copolymer coated with a cell adhesion promoter and a marking agent.
Claim 20
Independent Claim
48 words
A method for the therapeutic embolization of microspheres in a mammal which comprises administering to a mammal a microsphere, having a diameter ranging between about 10 to about 2000 μm, wherein said microsphere comprises a hydrophilic acrylic copolymer coated with a cell adhesion promoter and a marking agent.
Claim 21
Independent Claim
104 words
A method for the therapeutic embolization of microspheres in a mammal which comprises administering to a mammal a microsphere having a diameter ranging between about 10 to about 2000 μm, wherein said microsphere comprises a copolymer which comprises in copolymerized form about 25 to about 98% neutral hydrophilic acrylic monomer by weight, about 2 to about 50% difunctional monomer by weight, about 0 to about 50% by weight of one or more monomers having cationic charge, and about 1 to about 30% by weight of a functionalized monomer making possible the detection of the microsphere; said copolymer being coated with a cell adhesion promoter.
Claim 22
Independent Claim
104 words
A method for the therapeutic embolization of microspheres in a mammal which comprises administering to a mammal a microsphere having a diameter ranging between about 10 to about 2000 μm, wherein said microsphere comprises a copolymer which comprises in copolymerized form about 25 to about 98% neutral hydrophilic acrylic monomer by weight, about 2 to about 50% difunctional monomer by weight, about 0 to about 50% by weight of one or more monomers having cationic charge, and about 1 to about 30% by weight of a functionalized monomer making possible the detection of the microsphere; said copolymer being coated with a cell adhesion promoter.
Claim 23
Dependent Claim
16 words
An injectable solution according to claim 5, which comprises microspheres in approximately 200 μm caliber segments.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-07-14 | 2001-01-13 | 2001-07-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-07-14 | 2005-01-13 | 2005-07-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-07-14 | 2009-01-13 | 2009-07-15 | $7700.00 | Window Closed / Lapsed |